Compare VYLR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYLR | NTRA |
|---|---|---|
| Founded | 1802 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2B | 56.7B |
| IPO Year | 2026 | 2015 |
| Metric | VYLR | NTRA |
|---|---|---|
| Price | $74.39 | $402.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 23 |
| Target Price | $82.07 | ★ $403.89 |
| AVG Volume (30 Days) | ★ 4.7M | 1.5M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | N/A | $26.19 |
| Revenue Next Year | $3.56 | $20.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $65.11 | $181.00 |
| 52 Week High | $77.39 | $437.41 |
| Indicator | VYLR | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 56.53 |
| Support Level | $71.20 | $380.39 |
| Resistance Level | $76.13 | $437.41 |
| Average True Range (ATR) | 2.80 | 18.93 |
| MACD | -0.12 | -2.67 |
| Stochastic Oscillator | 56.55 | 39.34 |
Vylor is a seed and crop genetics pure-play company. The company was formed in 2026 when it was spun off from Corteva. Vylor is a leader in the development of genetically modified seeds and other advanced germplasm and traits that boost crop yields. The company operates in two segments based on geography—Americas and Rest of World. The Americas segment, which includes North and South America, generates most sales and profits.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.